Lung Biotechnology Public Benefit Corporation
- Country
- 🇺🇸United States
- Ownership
- Subsidiary
- Established
- 1997-01-01
- Employees
- 11
- Market Cap
- -
A Study With BPS-314d-MR-PAH-303 in Participants With Pulmonary Arterial Hypertension
- Conditions
- Pulmonary Arterial Hypertension
- Interventions
- Drug: Placebo
- First Posted Date
- 2018-09-04
- Last Posted Date
- 2020-09-07
- Lead Sponsor
- Lung Biotechnology PBC
- Target Recruit Count
- 112
- Registration Number
- NCT03657095
- Locations
- 🇺🇸
The University of Alabama at Birmingham, Birmingham, Alabama, United States
🇺🇸Cedars-Sinai Medical Center, Beverly Hills, California, United States
🇺🇸University of California San Diego Medical Center, La Jolla, California, United States
Beraprost-314d Added-on to Tyvaso® (BEAT)
- Conditions
- Pulmonary Arterial Hypertension
- Interventions
- Drug: Placebo
- First Posted Date
- 2013-07-26
- Last Posted Date
- 2020-08-03
- Lead Sponsor
- Lung Biotechnology PBC
- Target Recruit Count
- 273
- Registration Number
- NCT01908699
- Locations
- 🇺🇸
University of Alabama at Birmingham, Birmingham, Alabama, United States
🇺🇸Cedars-Sinai Medical Center Heart Institute, Beverly Hills, California, United States
🇺🇸Allianz Research Institute Inc., Fountain Valley, California, United States
A Multinational, Multicenter, Study to Assess the Efficacy and Safety of BPS-314d-MR in Subjects With Pulmonary Arterial Hypertension Currently Receiving Treatment With an Endothelin Receptor Antagonist and/or a Phosphodiesterase-5 Inhibitor
- Conditions
- Pulmonary Arterial Hypertension
- Interventions
- Drug: Placebo
- First Posted Date
- 2011-10-24
- Last Posted Date
- 2012-05-14
- Lead Sponsor
- Lung Biotechnology PBC
- Registration Number
- NCT01458236
Extension of BPS-MR-PAH-203 in Pulmonary Arterial Hypertension (PAH) Patients
- Conditions
- Pulmonary Arterial Hypertension
- Interventions
- First Posted Date
- 2009-10-06
- Last Posted Date
- 2019-09-16
- Lead Sponsor
- Lung Biotechnology PBC
- Target Recruit Count
- 31
- Registration Number
- NCT00990314
- Locations
- 🇺🇸
Harbor-UCLA Medical Center, Torrance, California, United States
🇺🇸Midwest Heart Foundation - Advocate Medical Group, Oakbrook Terrace, Illinois, United States
🇺🇸Albert Einstein College of Medicine, Bronx, New York, United States
Dose-response Study of the Safety and Efficacy of Beraprost Sodium Modified Release (BPS-MR) in Patients With Pulmonary Arterial Hypertension (PAH)
- Conditions
- Pulmonary Arterial Hypertension
- Interventions
- First Posted Date
- 2009-10-06
- Last Posted Date
- 2020-09-30
- Lead Sponsor
- Lung Biotechnology PBC
- Target Recruit Count
- 36
- Registration Number
- NCT00989963
- Locations
- 🇺🇸
Harbor-UCLA Medical Center, Torrance, California, United States
🇺🇸Edward Heart Hospital, Naperville, Illinois, United States
🇺🇸Albert Einstein College of Medicine, Bronx, New York, United States
An Open-Label Extension of BPS-MR-PAH-201 in Pulmonary Arterial Hypertension (PAH) Patients
- Conditions
- Pulmonary Arterial Hypertension
- Interventions
- First Posted Date
- 2008-11-18
- Last Posted Date
- 2019-12-26
- Lead Sponsor
- Lung Biotechnology PBC
- Target Recruit Count
- 18
- Registration Number
- NCT00792571
- Locations
- 🇺🇸
Harbor-UCLA Medical Center, Torrance, California, United States
🇺🇸Allegheny General Hospital, Pittsburgh, Pennsylvania, United States
🇺🇸UTSW Medical Center Dallas, Dallas, Texas, United States
A Multi-Center, Open-Label, Multiple Dose, Dose Finding Study Exploring the Safety and Tolerability of Beraprost Sodium Modified Release in PAH Patients
- Conditions
- Pulmonary Arterial Hypertension
- First Posted Date
- 2008-10-29
- Last Posted Date
- 2020-06-09
- Lead Sponsor
- Lung Biotechnology PBC
- Target Recruit Count
- 19
- Registration Number
- NCT00781885
- Locations
- 🇺🇸
Harbor-UCLA Medical Center, Torrance, California, United States
🇺🇸Allegheny General Hospital, Pittsburgh, Pennsylvania, United States
🇺🇸UTSW Medical Center, Dallas, Texas, United States
Effects of Inhaled Treprostinil Sodium for the Treatment of Pulmonary Hypertension Associated With Idiopathic Pulmonary Fibrosis
- Conditions
- Pulmonary HypertensionIdiopathic Pulmonary Fibrosis
- First Posted Date
- 2008-06-23
- Last Posted Date
- 2018-05-11
- Lead Sponsor
- Lung Biotechnology PBC
- Target Recruit Count
- 1
- Registration Number
- NCT00703339
- Locations
- 🇺🇸
UCSD Medical Center m/c7381, La Jolla, California, United States
🇺🇸UC Davis Medical Center/Advanced Lung Disease and LungTransplant Program, Sacramento, California, United States
🇺🇸University of Michigan, Ann Arbor, Michigan, United States